<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="/ProjectMundo/style/jats-html.xsl"?>
<!DOCTYPE response>
<article article-type="research-article" dtd-version="1.2" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    41467
   </journal-id>
   <journal-id journal-id-type="doi">
    10.1038/41467.2041-1723
   </journal-id>
   <journal-title-group>
    <journal-title>
     Nature Communications
    </journal-title>
    <abbrev-journal-title abbrev-type="publisher">
     Nat Commun
    </abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2041-1723
   </issn>
   <publisher>
    <publisher-name>
     Nature Publishing Group UK
    </publisher-name>
    <publisher-loc>
     London
    </publisher-loc>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">
    s41467-024-47940-y
   </article-id>
   <article-id pub-id-type="manuscript">
    47940
   </article-id>
   <article-id pub-id-type="doi">
    10.1038/s41467-024-47940-y
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Article
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/4017
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/699/255/2514
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/326/596/1553
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/1647/334/1874/345
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /45
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /45/22
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /82/29
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /45/70
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /45/77
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /45/29
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /38/22
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /38/1
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /64/60
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /82/80
     </subject>
    </subj-group>
    <subj-group subj-group-type="NatureArticleTypeID">
     <subject>
      article
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">
     Gene editing for latent herpes simplex virus infection reduces viral load and shedding in vivo
    </article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" id="Au1">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-1125-6856
     </contrib-id>
     <name name-style="western">
      <surname>
       Aubert
      </surname>
      <given-names>
       Martine
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au2">
     <name name-style="western">
      <surname>
       Haick
      </surname>
      <given-names>
       Anoria K.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au3">
     <name name-style="western">
      <surname>
       Strongin
      </surname>
      <given-names>
       Daniel E.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au4">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-9644-361X
     </contrib-id>
     <name name-style="western">
      <surname>
       Klouser
      </surname>
      <given-names>
       Lindsay M.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au5">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-2905-485X
     </contrib-id>
     <name name-style="western">
      <surname>
       Loprieno
      </surname>
      <given-names>
       Michelle A.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au6">
     <name name-style="western">
      <surname>
       Stensland
      </surname>
      <given-names>
       Laurence
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au7">
     <name name-style="western">
      <surname>
       Santo
      </surname>
      <given-names>
       Tracy K.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au8">
     <name name-style="western">
      <surname>
       Huang
      </surname>
      <given-names>
       Meei-Li
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au9">
     <name name-style="western">
      <surname>
       Hyrien
      </surname>
      <given-names>
       Ollivier
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au10">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-1619-7541
     </contrib-id>
     <name name-style="western">
      <surname>
       Stone
      </surname>
      <given-names>
       Daniel
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
    </contrib>
    <contrib contrib-type="author" corresp="yes" id="Au11">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-8212-3789
     </contrib-id>
     <name name-style="western">
      <surname>
       Jerome
      </surname>
      <given-names>
       Keith R.
      </given-names>
     </name>
     <address>
      <email>
       kjerome@fredhutch.org
      </email>
     </address>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="corresp" rid="IDs4146702447940y_cor11">
      m
     </xref>
    </contrib>
    <aff id="Aff1">
     <label>
      1
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/007ps6h72
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.270240.3
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2180 1622
      </institution-id>
      <institution content-type="org-division">
       Vaccine and Infectious Disease Division
      </institution>
      <institution content-type="org-name">
       Fred Hutchinson Cancer Center
      </institution>
     </institution-wrap>
     <addr-line content-type="postcode">
      98109
     </addr-line>
     <addr-line content-type="city">
      Seattle
     </addr-line>
     <addr-line content-type="state">
      WA
     </addr-line>
     <country country="US">
      USA
     </country>
    </aff>
    <aff id="Aff2">
     <label>
      2
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00cvxb145
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.34477.33
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2298 6657
      </institution-id>
      <institution content-type="org-division">
       Department of Laboratory Medicine and Pathology
      </institution>
      <institution content-type="org-name">
       University of Washington
      </institution>
     </institution-wrap>
     <addr-line content-type="postcode">
      98133
     </addr-line>
     <addr-line content-type="city">
      Seattle
     </addr-line>
     <addr-line content-type="state">
      WA
     </addr-line>
     <country country="US">
      USA
     </country>
    </aff>
   </contrib-group>
   <author-notes>
    <corresp id="IDs4146702447940y_cor11">
     <label>
      m
     </label>
     <email>
      kjerome@fredhutch.org
     </email>
    </corresp>
   </author-notes>
   <pub-date date-type="pub" publication-format="electronic">
    <day>
     13
    </day>
    <month>
     5
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <pub-date date-type="collection" publication-format="electronic">
    <month>
     12
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <volume>
    15
   </volume>
   <issue seq="4018">
    1
   </issue>
   <elocation-id>
    4018
   </elocation-id>
   <history>
    <date date-type="registration">
     <day>
      17
     </day>
     <month>
      4
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="received">
     <day>
      22
     </day>
     <month>
      1
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="accepted">
     <day>
      15
     </day>
     <month>
      4
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="online">
     <day>
      13
     </day>
     <month>
      5
     </month>
     <year>
      2024
     </year>
    </date>
   </history>
   <permissions>
    <copyright-statement content-type="compact">
     © The Author(s) 2024
    </copyright-statement>
    <copyright-year>
     2024
    </copyright-year>
    <copyright-holder>
     The Author(s)
    </copyright-holder>
    <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
     <license-p>
      <bold>
       Open Access
      </bold>
      This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
      <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
       http://creativecommons.org/licenses/by/4.0/
      </ext-link>
      .
     </license-p>
    </license>
   </permissions>
   <abstract id="Abs1" xml:lang="en">
    <title>
     <bold>
      Abstract
     </bold>
    </title>
    <p id="Par1">
     Vifaa vya kudhibiti HSV ni tu ya kusimamia kwa sababu hawawezi kusambaza HSV inayokuwa na maambukizi katika nyuzi za ganglionic, chombo cha magonjwa yanayotokana mara kwa mara. Tumeandaa njia yenye uwezo wa kufanya afya bora dhidi ya magonjwa ya HSV, yanayohusika na uharakati wa gene kwa kutumia meganucleases yanayohusiana na HSV yanayotolewa na virusi za adeno-associated (AAV). Uharakati wa gene uliyofanyika kwa kutumia meganucleases mbili yanayohusiana na HSV-1 yanayotolewa na pamoja ya AAV9, AAV-Dj/8, na AAV-Rh10 inaweza kusambaza 90% au zaidi ya DNA ya HSV inayokuwa na maambukizi katika mfumo wa pima kusini wa pumzi, na hadi 97% ya DNA ya HSV inayokuwa na maambukizi katika mfumo wa pima kusini wa kijamii. Kwa kutumia njia ya dawa ya kurejelea HSV-1 inayokuwa na maambukizi, tumeonyesha kuwa kusambaza viwango vya virusi vya ganglionic vinavyoweza kusababisha ongezeko mkubwa wa kurejelea virusi katika mice wanawake waliotafadhaliwa. Ingawa mifano ya afya bora yamekuwa na uwezo wa kutolewa, katika baadhi ya mawasiliano, tumeona hepatotoxicity katika dozi makubwa na uwezo wa kutoa maelezo mikubwa ya maambukizi ya neurons bila alama za kinauzi au nyepesi. Kupunguza mifano kwa kutumia serotype moja (AAV9) yanayotolea meganuclease moja yanayohusiana na sehemu isiyofanana ya genome ya HSV, kupunguza dozi, na kutumia promoter ya neurons-specific kila moja inatoa uwezo wa kutolewa zaidi wakati kufanya kazi. Matokeo haya yanayoweza kujenga uwezo wa kufanya afya bora wa uharakati wa gene kwa magonjwa ya HSV.
    </p>
   </abstract>
   <abstract abstract-type="ShortSummary" id="Abs2" xml:lang="en">
    <p id="Par2">
     The main challenge for anti-HSV therapy is to target latent virus in ganglionic neurons. Here, the authors report a well-tolerated anti-HSV gene editing approach against HSV which targets latent HSV genomes and leads to reductions of ganglionic viral loads, and viral shedding upon reactivation in mouse models.
    </p>
   </abstract>
   <funding-group>
    <award-group>
     <funding-source>
      <institution-wrap>
       <institution>
        National Institutes of Health grant R01AI132599 National Institutes of Health grant 5P50AR065139 National Institutes of Health / National Cancer Institutes, Cancer Center Support Grant P30 CA015704 Caladan Foundation Kenneth Hill Foundation Krieger Family Trust Tiny Foundation over 2000 individual donors
       </institution>
      </institution-wrap>
     </funding-source>
    </award-group>
   </funding-group>
   <custom-meta-group>
    <custom-meta>
     <meta-name>
      publisher-imprint-name
     </meta-name>
     <meta-value>
      Nature Portfolio
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-issue-count
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-article-count
     </meta-name>
     <meta-value>
      4018
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-pricelist-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-holder
     </meta-name>
     <meta-value>
      Springer Nature Limited
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-contains-esm
     </meta-name>
     <meta-value>
      Yes
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-month
     </meta-name>
     <meta-value>
      4
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-day
     </meta-name>
     <meta-value>
      17
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-product
     </meta-name>
     <meta-value>
      NonStandardArchiveJournal
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-grants-type
     </meta-name>
     <meta-value>
      OpenChoice
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      metadata-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      abstract-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodypdf-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodyhtml-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bibliography-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      esm-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      online-first
     </meta-name>
     <meta-value>
      false
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-file-reference
     </meta-name>
     <meta-value>
      BodyRef/PDF/41467_2024_Article_47940.pdf
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-type
     </meta-name>
     <meta-value>
      Typeset
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      target-type
     </meta-name>
     <meta-value>
      OnlinePDF
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-type
     </meta-name>
     <meta-value>
      OriginalPaper
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-primary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-collection
     </meta-name>
     <meta-value>
      Science (multidisciplinary)
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      open-access
     </meta-name>
     <meta-value>
      true
     </meta-value>
    </custom-meta>
   </custom-meta-group>
  </article-meta>
 </front>
 <body>
  <sec id="Sec1" sec-type="introduction">
   <title>
    Ujumbe
   </title>
   <p id="Par3">
    Mafunguo ya HSV yanaweza kusababisha matatizo yanayotokana mara kwa mara kwenye mawili na kifupi, kikoma, anogenital, au matatizo mengine, na mafunguo yanayohusiana na watoto wanaozaliwa yanaweza kusababisha umaskini wa kibinadamu na athari za kibinadamu za kibigori. Mafunguo ya genitali yanayohusiana na HSV-2 yanazidhi hatari ya kupata HIV, na ni mzunguko muhimu wa pandemiki ya HIV duniani
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
    </sup>
    . Thamani ya antiviral inaweza kusaidia matatizo ya mara kwa mara na kusimamia vikwazo, lakini haitawafikia mafunguo yanayotokana mara kwa mara
    <sup>
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
     ,
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
     ,
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
     ,
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
     ,
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
    </sup>
    . Vikwazo vya mara kwa mara vinajulikana kwa uwezo wa HSV wa kujenga mafunguo yanayotokana mara kwa mara ndani ya neoroni za ganglionic zinazokusambaza mahali yanayohusiana. Mafunguo yanayotokana mara kwa mara ya HSV kwenye ganglia hazitathminiwa na antiviral za kawaida, kwa hiyo inaonekana sababu ya kutokujulikana kwa antiviral za kufungua, na vikwazo vya mara kwa mara vinaanza mara tatu mara moja kwa mara moja baada ya kufungua.
   </p>
   <p id="Par4">
    Stratejia ya kufungua yanayotokana mara kwa mara yanayotambua ni gene editing yanayohusiana na HSV yanayotokana mara kwa mara
    <sup>
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
    </sup>
    . Katika utafiti uliopita hivi karibuni, meganucleases yanayohusiana na AAV yameondolewa zaidi ya 90% ya genomes ya HSV-1 kutoka kwenye ganglia ya cervical ya superior ya mifuko yanayotokana mara kwa mara
    <sup>
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
    </sup>
    . Ingawa kuna tofauti hii nzuri ya mafunguo yanayotokana mara kwa mara ya HSV baada ya gene editing, umuhimu wa tofauti hii kwa mafunguo ya HSV yanayohusiana na binadamu haijapewa kubali. Wanafunguo hawana kuhofu na mafunguo yanayotokana mara kwa mara ya HSV kwa uhamiaji, bali bado kuhusu matatizo yanayohusiana na alama na/va kusambaza vya virus, na hatari yanayohusiana na kupitisha kwa wengine
    <sup>
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
    </sup>
    . Mifumo ya mifuko yanayohusiana na paka yanayotokana mara kwa mara yanahisi katika uwezo wao wa kusambaza maswala haya, kwa sababu paka yanayotokana mara kwa mara yanaweza kusambaza HSV mara tatu mara moja au kusambaza kusambaza vya virus kwenye matumbo yanayohusiana.
   </p>
   <p id="Par5">
    Hapa, tunapopatafuta mifumo ya induction ya HSV-1 ya mara tatu mara moja na kusambaza vya virus kwenye paka yanayotokana mara kwa mara, na kujihusisha kwamba gene editing inaathiri tofauti nzuri sana si tu kwenye mafunguo yanayotokana mara kwa mara ya HSV, bali pia kwenye kusambaza vya virus yanayohusiana. Usimamizi wa mbinu ya kifunguo kwa njia ya kusimamia mifumo, kusimamia dozi, na kusimamia neoroni za kusambaza vya meganuclease inatoa matokeo ya kufikia kusambaza sana ya athari yanayohusiana na kibinadamu na ganglia, inayusaidia kujenga mbinu ya kifunguo kliniki.
   </p>
  </sec>
  <sec id="Sec2" sec-type="results">
   <title>
    Matokeo
   </title>
   <sec id="Sec3">
    <title>
     Ufanisi wa meganuclease hupunguza mizigo ya vayiro katika ganglion baada ya uchafu wa macho au uchafu wa kijamii na HSV
    </title>
    <p id="Par6">
     Tulipatafuta AAV serotypes nyingi kwa kusambaza meganucleases kwenye paka yanayotokana mara kwa mara, na tulipata matokeo nzuri zaidi na AAV-Rh10, ili kususishwa na AAV8 na AAV1
     <sup>
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
     </sup>
     . Ili kusimamia matokeo zaidi, tulipatafuta AAV serotypes nyingi zaidi, kama vile AAV7, AAV9, AAV-DJ, na AAV-DJ/8, kwa kusambaza anti-HSV1 meganuclease, m5, kwa dozi ya 10 AAV genomes (vg) kwa paka (Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1a
     </xref>
     ), kwa kutumia mifumo wetu wa mafunguo ya HSV ya orofacial. AAV9 na AAV-Dj/8 yalikuwa zaidi bora kuliko 10 vg AAV-Rh10, yaani ya mifumo yetu zinazotumika kwa mara kwanza, yanayonyesha tofauti ya HSV kwenye ganglia ya cervical ya superior (SCG) ya 95% (
     <italic>
      p
     </italic>
     = 10) na 90% (
     <italic>
      p
     </italic>
     = 0.018), kwa kawaida, kulingana na zinazotumika kwa mara kwanza (Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1b
     </xref>
     ), yanayonyesha tofauti ya 65% yanayotumika kwa m5 peke yake kwa kutumika na AAV-Rh10
     <sup>
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
     </sup>
     . Vilevile, AAV9 na AAV-Dj/8 yalikuwa zaidi bora kuliko AAV-Rh10 kwenye ganglia ya trigeminal (TG), yanayonyesha tofauti ya HSV ya 48% (
     <italic>
      p
     </italic>
     = 0.07) na 41% (
     <italic>
      p
     </italic>
     = 0.5), kwa kawaida (Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1b
     </xref>
     ), kulingana na matokeo yetu ya awali yanayonyesha tofauti yanayohusiana na kutumia AAV-Rh10 kwa kutumia m5
     <sup>
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
     </sup>
     . Njia ya kutumia AAV (vein ya retro-orbital vs. intradermally kwenye whisker pad) haikuwa na athari yanayohusiana na AAV transduction au gene editing efficiencies (Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1e–g
     </xref>
     ).
    </p>
    <p id="Par7"/>
    <p id="Par8">
     Wakati maambukizi ya kifupi na HSV ni ya kawaida sana, maambukizi ya kigenitali, ambayo yanatoa maambukizi ya latenti ya ganglia ya mizizi ya mgeni (DRG), pia yanahakikisha sababu kubwa ya uchovu. Kwa hiyo tumejaza maambukizi ya latenti ya kigenitali katika mice kwa kujaza HSV-1 kwenye mgeni baada ya utaratibu wa Depo Provera, ambao unatengeneza mazingira ya estrus na kuboresha maambukizi ya HSV
     <sup>
      <xref ref-type="bibr" rid="CR13">
       13
      </xref>
     </sup>
     . Mice ambao walikuwa tayari ameambukizwa walipatikana kwa jumla ya 3 × 10 vg ya mchanganyiko wa AAV9, AAV-Dj/8, na AAV-Rh10 yanayohatimiwa kwa meganucleases mbili ya HSV1-specific mara moja (m5 pamoja na m8, ambayo hutoa maoni kwenye mstari wa
     <italic>
      UL30
     </italic>
     ambayo unahifadhi kodi ya subuniti ya kataliti ya DNA polymerase ya virus
     <sup>
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
     </sup>
     . Kwa paraleli, tumejaribu mchanganyiko wa AAV huo hapa juu ya maambukizi ya latenti ya HSV ya kifupi kama tumeandikia hapa juu (Fig.
     <xref ref-type="fig" rid="Fig1">
      1a, b
     </xref>
     ). Kwa njia kama yoyote, ufanisi katika mfumo wa maambukizi ya kigenitali ulikuwa ni juu zaidi tumeonekana tarehe hii, kwa kuchunguza 97.7% katika load ya virus ya HSV katika DRG (Fig.
     <xref ref-type="fig" rid="Fig1">
      1c
     </xref>
     ). Hii ilikuwa na mazoezi bora na kundi la maambukizi ya kifupi lililojaribu kwa paraleli, ambalo (kulingana na mafunzo yetu ya zamani) tumeonekana gene editing ya kujenga na kuchunguza load za HSV ya ganglia ya 89% katika SCG na 61% katika TG (Fig.
     <xref ref-type="fig" rid="Fig1">
      1d, e
     </xref>
     ).
     <fig id="Fig1" position="float">
      <label>
       Fig. 1
      </label>
      <caption xml:lang="sw">
       <title>
        Onyesho ya viungo vya HSV katika ganglia baada ya makanisa meganuclease kutoka kwa ulemavu wa kijamii na macho.
       </title>
       <p>
        <bold>
         a
        </bold>
        ,
        <bold>
         b
        </bold>
        Muda wa utaratibu wa (
        <bold>
         a
        </bold>
        ) ulemavu wa kijamii au (
        <bold>
         b
        </bold>
        ) ulemavu wa macho na makanisa meganuclease. RO, retroorbital; TV, mivimba ya pembe.
        <bold>
         c
        </bold>
        Viungo vya HSV katika DRGs kutoka kwa faragha (
        <italic>
         n
        </italic>
        = 7) na faragha iliyopewa meganuclease mara mbili (
        <italic>
         n
        </italic>
        = 4) ambao walikuwa tayari tayari na HSV-1;
        <italic>
         p
        </italic>
        = 0.001.
        <bold>
         d
        </bold>
        . Viungo vya HSV katika SCGs na TGs kutoka kwa faragha (
        <italic>
         n
        </italic>
        = 10) na faragha iliyopewa meganuclease mara mbili (
        <italic>
         n
        </italic>
        = 10) ambao walikuwa tayari tayari na HSV-1;
        <italic>
         p
        </italic>
        = 0.0046 na 0.0034 kwa SCG na TG, kwa ujumla.
        <bold>
         e
        </bold>
        Kurekebisha gene kwenye mstari m5 wa virus iliyobaki iliyotathmini kwa T7E1 assay katika SCG na TG kutoka kwa faragha iliyopewa meganuclease mara mbili (
        <italic>
         n
        </italic>
        = 10). Kila grafu ina thamani za kawaida na thamani za kijamii pamoja na onyesho ya viungo vya HSV katika faragha iliyopewa meganuclease mara mbili kulingana na faragha na statistical analysis (unpaired one-tailed Mann-Whitney test with **
        <italic>
         p
        </italic>
        &lt; 0.01). Viungo vya AAV vinavyoronyeshwa katika Supplemental Fig.
        <xref ref-type="supplementary-material" rid="MOESM1">
         9a, b
        </xref>
        . Data za kujenga zinapatikana kama Source Data file.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-47940-y/41467_2024_47940_Fig1_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec4">
    <title>
     Unganisho wa vayiro ya HSV kwa kutumia magwana ya BET bromodomain JQ1
    </title>
    <p id="Par9">
     Mice kawaida hawapokubali maambukizi ya HSV, na kuna virusi kidogo au hakuna katika maeneo ya peripheri, yanayokurangisha umuhimu wao katika mafunzo ya cure. BET (Bromo na Extra-Terminal domain) inhibitor ya bromodomain JQ1 iliruhusiwa kutoa maambukizi ya latenti ya HSV katika mtaalamu katika mazingira ya neuronal, na HSV ilikuwa inaweza kuhusishwa katika macho ya mice ambao walikuwa tayari ameambukizwa na JQ1
     <sup>
      <xref ref-type="bibr" rid="CR14">
       14
      </xref>
     </sup>
     . Kutoathiri umuhimu wa JQ1 kwa ajili ya kazi yetu ya cure, tumeongeza mafunzo haya kwa kujaribu kujua kinetics ya kwanza ya shedding ya HSV baada ya therapy ya JQ1.
    </p>
    <p id="Par10">
     Kujaza mara moja kwenye mgeni (IP) ya JQ1 (50 mg/kg) kwenye mice ambao walikuwa tayari ameambukizwa (Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3a
     </xref>
     ) ilitoa shedding inayoweza kuhusishwa kutoka kwenye macho ya 56% (5/9) ya animals, kulingana na 0/9 animals ambao walipatikana kwa vehicle pekee (Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3b, c
     </xref>
     ). Viral shedding ilikuwa ina muda mfupi, inapokua kwa siku 2 baada ya JQ1, na load za virusi zinazoweza kuhusishwa zinazokua kati ya 10 hadi karibu 10 copies/swab (Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3c
     </xref>
     ). Uhusiano wa kwanza ulionekana kuwa JQ1 inaweza kuwa ni stimulus ya reactivation ya kuchunguza zaidi kwa HSV kuliko hyperthermic stress (HS), ambayo katika mikono yangu yalinipatia shedding ya virusi inayoweza kuhusishwa kwenye zaidi ya 20% ya animals (2/12 HS vs 4/10 JQ1), na load za virusi za shedding za kipindi kubwa zinazokuwa mara mbili zaidi chini kuliko baada ya treatment ya JQ1 (Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3d–f
     </xref>
     ). Treatment ya mara mara kwa JQ1 kwa muda wa siku moja kati ya mara mara ilitoa episodes za shedding mara mara na kinetics sawa kama iliyotolewa hapa juu (Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S4a–e
     </xref>
     ). Kwa muda wa mara mara 3 za JQ1 reactivations (Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S4e
     </xref>
     ), shedding kutoka kwenye mice wachache ilikuwa kina uchunguza; 10/12 (83%) mice walitoa virusi inayoweza kuhusishwa mara moja au zaidi, lakini tu 1/12 (8%) walitoa baada ya mara mara zote tatu, wakati 4/12 (33%) na 5/12 (42%) walitoa tu baada ya mara mara mbili au moja ya mara mara tatu, kwa mara kwa mara (Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S4e
     </xref>
     na Table
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1
     </xref>
     ). Shedding ilikuwa kina uchunguza mara nyingi (inayoweza kuhusishwa tu kwenye macho moja), hasa kwa sababu kujaza kwanza ilikuwa kwenye macho mawili (shedding ya kina uchunguza iliyotolewa katika 33/37 (89%) ya events). Nyaraka ya shedding kwenye kipindi moja ilikuwa si kina uchunguza ya nyaraka ya events za shedding za kipindi zinazofuata (Table
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1
     </xref>
     ). Kwa njia kama yoyote kwa mafunzo ya cure, reactivation mara mara kwa wiki kwa JQ1 hadi 7 injections mara mara kwa wiki hakuchunguza load za virusi ya ganglia kulingana na animals za control (Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S4g, h
     </xref>
     )
     <sup>
      <xref ref-type="bibr" rid="CR15">
       15
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec5">
    <title>
     Punguzi ya mizigo ya vayiro ya HSV katika ganglion inatoa mizigo ya vayiro ya peripheri
    </title>
    <p id="Par11">
     <fig id="Fig2" position="float">
      <label>
       Fig. 2
      </label>
      <caption xml:lang="sw">
       <title>
        Onyesho ya kurekebisha virus katika faragha iliyopewa meganuclease.
       </title>
       <p>
        Muda wa utaratibu wa ulemavu wa macho, makanisa meganuclease na reactivations ya virus kwa JQ1.
        <bold>
         a
        </bold>
        Utaratibu 1 (
        <italic>
         n
        </italic>
        = 10 kwa kila kundi). Viungo vya HSV katika SCGs (
        <bold>
         b
        </bold>
        :
        <italic>
         p
        </italic>
        = 0.0057) na TGs (
        <bold>
         c
        </bold>
        ). Onyesho ya viungo vya HSV katika faragha iliyopewa meganuclease mara mbili kulingana na faragha na statistical analysis (unpaired one-tailed Mann–Whitney test with ns: sio ya kumbukumbu, **
        <italic>
         p
        </italic>
        &lt; 0.01) zinazohusishwa. Kurekebisha gene kwenye mstari m5 wa virus iliyobaki iliyotathmini kwa T7E1 assay katika SCG na TG kutoka kwa faragha iliyopewa meganuclease mara mbili (
        <bold>
         d
        </bold>
        ). Viungo vya HSV katika swab zinazochukuliwa kila siku kutoka siku 1 hadi 4 baada ya reactivation kwa JQ1 kutoka kwa faragha (
        <bold>
         e
        </bold>
        ) na faragha iliyopewa meganuclease mara mbili (
        <bold>
         f
        </bold>
        ). Panza 2i-k zinaonyesha data kwa SCG na TG zote kwa kila faragha. Onyesho ya area under the curve (AUC) analysis (
        <bold>
         g
        </bold>
        ) na
        <italic>
         p
        </italic>
        value (un
        <italic>
         p
        </italic>
        aired one-tailed Mann–Whitney test). Viungo vya AAV vinavyoronyeshwa katika Supplemental Fig.
        <xref ref-type="supplementary-material" rid="MOESM1">
         9c, d
        </xref>
        . Kila grafu ina thamani za kawaida na thamani za kijamii pamoja na onyesho ya viungo vya HSV. Data za kujenga zinapatikana kama Source Data file.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-47940-y/41467_2024_47940_Fig2_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
     <fig id="Fig3" position="float">
      <label>
       Fig. 3
      </label>
      <caption xml:lang="en">
       <title>
        Onyesho la kusimamia vinywaji vya kibinafsi katika ndege zilizotolewa na meganuclease.
       </title>
       <p>
        Maeneo ya utafiti wa uchunguzi wa macho, ushirikiano wa meganuclease na vinywaji vya virus kwa JQ1.
        <bold>
         a
        </bold>
        Utafiti 2 (
        <italic>
         n
        </italic>
        = 8 kwa kila kundi). Matumizi ya HSV katika SCGs (
        <bold>
         b
        </bold>
        ) na TGs (
        <bold>
         c
        </bold>
        ). Porsentaji ya onyesho la kusimamia matumizi ya HSV katika ndege zilizotolewa na meganuclease mara kwa mara na ndege zilizotolewa kwa kawaida na tathmini ya takwimu (unpaired one-tailed Mann-Whitney test na ns: si ya muhimu, **
        <italic>
         p
        </italic>
        &lt; 0.01) zinazohusishwa. Usimamizi wa gene kwenye mstari m5 wa virus zilizobaki zinazotathminiwa kwa T7E1 assay katika SCG na TG kutoka kwa ndege zilizotolewa na meganuclease mara kwa mara (
        <bold>
         d
        </bold>
        ). Matiti ya HSV katika swab zilizochukuliwa kila siku kutoka tarehe 1 hadi 4 baada ya reactivation kwa JQ1 kutoka kwa ndege zilizotolewa kwa kawaida (
        <bold>
         e
        </bold>
        ) na ndege zilizotolewa na meganuclease mara kwa mara (
        <bold>
         f
        </bold>
        ). Maeneo 2
        <bold>
         b
        </bold>
        -
        <bold>
         d
        </bold>
        zinazonyesha data kwa SCG zote na TG zote kutoka kwa kila ndege. Tathmini ya area under the curve (AUC) (
        <bold>
         g
        </bold>
        ) na
        <italic>
         p
        </italic>
        value (un
        <italic>
         p
        </italic>
        aired one-tailed Mann–Whitney test). Matumizi ya AAV zinazonyeshwa katika Supplemental Fig.
        <xref ref-type="supplementary-material" rid="MOESM1">
         9e, f
        </xref>
        . Kila grafu inayonyesha thamani za kawaida na standard deviation. Data za chanzo zinazotolewa kama Source Data file.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-47940-y/41467_2024_47940_Fig3_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec6">
    <title>
     Usalama wa ufanisi wa AAV/meganuclease
    </title>
    <p id="Par12">
     <fig id="Fig4" position="float">
      <label>
       Fig. 4
      </label>
      <caption xml:lang="en">
       <title>
        Onyesho la kusimamia vinywaji vya kibinafsi katika ndege zilizotolewa na meganuclease.
       </title>
       <p>
        <bold>
         a
        </bold>
        Maeneo ya utafiti wa uchunguzi wa macho, ushirikiano wa meganuclease na vinywaji vya virus kwa JQ1.
        <bold>
         b
        </bold>
        ,
        <bold>
         c
        </bold>
        Matumizi ya HSV na
        <bold>
         d
        </bold>
        ,
        <bold>
         e
        </bold>
        , matumizi ya AAV katika SCGs (
        <bold>
         b
        </bold>
        ;
        <italic>
         p
        </italic>
        = 0.0016, 0.0012, na &lt;0.0001 kwa 0.6, 1.2, na 1.8 × 10
        <sup>
         12
        </sup>
        , kwa kawaida,
        <bold>
         d
        </bold>
        ) na TGs (
        <bold>
         c
        </bold>
        ;
        <italic>
         p
        </italic>
        = 0.068, 0.0025 na 0.0016 kwa 0.6, 1.2, na 1.8 × 10
        <sup>
         12
        </sup>
        , kwa kawaida,
        <bold>
         e
        </bold>
        ) katika ndege zilizotolewa kwa virus (
        <italic>
         n
        </italic>
        = 11) na ndege zilizotolewa kwa ushirikiano wa mara kwa mara uliowasilishwa kwa 0.6 (
        <italic>
         n
        </italic>
        = 12), 1.2 (
        <italic>
         n
        </italic>
        = 12), au 1.8 (
        <italic>
         n
        </italic>
        = 12) × 10
        <sup>
         12
        </sup>
        matumizi ya AAV dose. Porsentaji ya onyesho la kusimamia matumizi ya HSV katika ndege zilizotolewa na meganuclease mara kwa mara na ndege zilizotolewa kwa kawaida na tathmini ya takwimu (ordinary one-way Anova, multiple comparisons na ns: si ya muhimu, **
        <italic>
         p
        </italic>
        &lt; 0.01, ****
        <italic>
         p
        </italic>
        &lt; 0.0001) zinazohusishwa.
        <bold>
         f
        </bold>
        –
        <bold>
         i
        </bold>
        Matiti ya virus katika swab zilizochukuliwa kila siku kutoka tarehe 1 hadi 4 baada ya kila JQ1 reactivation kutoka kwa ndege zilizotolewa kwa kawaida (
        <bold>
         f
        </bold>
        ) na ndege zilizotolewa kwa ushirikiano wa mara kwa mara uliowasilishwa kwa 0.6 (
        <bold>
         g
        </bold>
        ), 1.2 (
        <bold>
         h
        </bold>
        ), au 1.8 (
        <bold>
         i
        </bold>
        ) ×10
        <sup>
         12
        </sup>
        matumizi ya AAV dose.
        <bold>
         j
        </bold>
        –
        <bold>
         l
        </bold>
        Tathmini ya area under the curve (AUC) ana
        <bold>
         l
        </bold>
        ysis ya vinywaji vya virus baada ya kwanza (
        <bold>
         j
        </bold>
        ), pili (
        <bold>
         k
        </bold>
        ), na tatu (
        <bold>
         l
        </bold>
        ) JQ1 reactivation kutoka kwa ndege zilizotolewa kwa virus (
        <italic>
         n
        </italic>
        = 11) na ndege zilizotolewa kwa ushirikiano wa mara kwa mara uliowasilishwa kwa 0.6 (
        <italic>
         n
        </italic>
        = 12), 1.2 (
        <italic>
         n
        </italic>
        = 12) au 1.8 (
        <italic>
         n
        </italic>
        = 12) × 10
        <sup>
         12
        </sup>
        matumizi ya AAV dose.
        <italic>
         p
        </italic>
        values (unpaired, ordinary one-way Anova, na multiple comparisons) zinazohusishwa kati ya kundi za ushirikiano na kundi cha kawaida. Kila grafu inayonyesha thamani za kawaida na standard deviation. Data za chanzo zinazotolewa kama Source Data file.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-47940-y/41467_2024_47940_Fig4_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
     <fig id="Fig5" position="float">
      <label>
       Fig. 5
      </label>
      <caption xml:lang="sw">
       <title>
        Shindano la virusi kwenye mahali pa nje kufungwa katika ndege zilizotolewa na meganuclease mbili.
       </title>
       <p>
        <bold>
         a
        </bold>
        Mipimo ya utaratibu wa uchafu wa macho, ushirikiano wa meganuclease na matukio ya reactivation ya virusi kwa JQ1.
        <bold>
         b
        </bold>
        Shindano la HSV kwenye SCGs (
        <bold>
         b
        </bold>
        ;
        <italic>
         p
        </italic>
        = 0.0012, na &lt;0.0001 kwa CTRL vs AAV/MN hasa JQ1 na kwa CTRL vs AAV/MN 2x JQ1, mara kwa mara), na TGs (
        <bold>
         c
        </bold>
        ;
        <italic>
         p
        </italic>
        = 0.0089, na 0.0293 kwa CTRL vs AAV/MN hasa JQ1 na kwa CTRL vs AAV/MN 2x JQ1, mara kwa mara) kwa ndege zilizotambuliwa na uchafu au zilizotambuliwa na uchafu na zilizotolewa na ushirikiano wa mbili na dozi ya AAV jumla ya 1.8 × 10
        <sup>
         12
        </sup>
        au zilizotambuliwa na uchafu na zilizotolewa na ushirikiano wa mbili na dozi ya AAV jumla ya 1.8 × 10
        <sup>
         12
        </sup>
        , kwa
        <italic>
         n
        </italic>
        = 12 kwa kila kundi. Porsenti ya shindano la HSV kwenye ndege zilizotolewa na ushirikiano mara kwa mara na ndege zilizotambuliwa na uchafu na tathmini ya takwimu (unpaired one-tailed Mann-Whitney test kwa *
        <italic>
         p
        </italic>
        &lt; 0.05; **
        <italic>
         p
        </italic>
        &lt; 0.01, ****
        <italic>
         p
        </italic>
        &lt; 0.0001) zinazohusishwa.
        <bold>
         d
        </bold>
        ,
        <bold>
         e
        </bold>
        Viti vya virusi kwenye swab zilizochukuliwa kila siku tangu siku ya 1 hadi 4 baada ya reactivation ya JQ1 mara mara mbili kwa wiki (mavi nyekundu) kutoka kwa ndege zilizotambuliwa na uchafu (
        <bold>
         d
        </bold>
        ) na ndege zilizotambuliwa na uchafu na zilizotolewa na ushirikiano wa mbili na dozi ya AAV jumla ya 1.8 × 10
        <sup>
         12
        </sup>
        (
        <bold>
         e
        </bold>
        ).
        <bold>
         f
        </bold>
        ,
        <bold>
         g
        </bold>
        Tathmini ya area under the curve (AUC) baada ya reactivation ya JQ1 ya kwanza (
        <bold>
         f
        </bold>
        ), na ya pili (
        <bold>
         g
        </bold>
        ) kutoka kwa ndege zilizotambuliwa na uchafu au zilizotambuliwa na uchafu na zilizotolewa na ushirikiano wa mbili na dozi ya AAV jumla ya 1.8 × 10
        <sup>
         12
        </sup>
        au zilizotambuliwa na uchafu na zilizotolewa na ushirikiano wa mbili na dozi ya AAV jumla ya 1.8 × 10
        <sup>
         12
        </sup>
        , kwa
        <italic>
         n
        </italic>
        = 12 kwa kila kundi.
        <italic>
         p
        </italic>
        values (unpaired one-tailed Mann–Whitney test) zinazohusishwa. Kila grafu ina thamani za ndege zilizotambuliwa na uchafu na thamani za kijani. AAV loads zinazohusishwa kwenye Supplemental Fig.
        <xref ref-type="supplementary-material" rid="MOESM1">
         9g–h
        </xref>
        . Data za kuzingatia zinazotolewa kama Source Data file.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-47940-y/41467_2024_47940_Fig5_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec7">
    <title>
     Punguzi ya dozi ya AAV/meganuclease ya ufanisi wa wanyama wenye uchafu wa kijamii hupunguza mizigo ya vayiro ya HSV katika DRG na inaweza kupunguza vayiro ya HSV ya kijamii
    </title>
    <p id="Par13">
     <fig id="Fig6" position="float">
      <label>
       Fig. 6
      </label>
      <caption xml:lang="sw">
       <title>
        Shindano la virusi kwenye mahali pa nje kufungwa katika ndege zilizotolewa na meganuclease mbili.
       </title>
       <p>
        <bold>
         a
        </bold>
        Mipimo ya utaratibu wa uchafu wa macho, ushirikiano wa meganuclease na matukio ya reactivation ya virusi kwa JQ1.
        <bold>
         b
        </bold>
        Shindano la HSV kwenye DRGs kutoka kwa ndege zilizotambuliwa na uchafu na zilizotolewa na reactivation ya JQ1 mara mara 3 mara kwa wiki na ndege zilizotambuliwa na uchafu na zilizotolewa na ushirikiano wa mbili au zilizotolewa na reactivation ya JQ1 mara mara 3 mara kwa wiki kwa
        <italic>
         n
        </italic>
        = 8 kwa kila kundi;
        <italic>
         p
        </italic>
        = 0.0055, na 0.0198 (ordinary one-way Anova, multiple comparisons) kwa CTRL + JQ1 vs AAV/MN hasa JQ1 na kwa CTRL + JQ1 vs AAV/MN + JQ1, mara kwa mara.
        <bold>
         c
        </bold>
        ,
        <bold>
         d
        </bold>
        Viti vya HSV kwenye swab zilizochukuliwa kila siku tangu siku ya 1 hadi 4 baada ya reactivation ya JQ1 (mavi nyekundu) kutoka kwa ndege zilizotambuliwa na uchafu (
        <bold>
         c
        </bold>
        ) na ndege zilizotambuliwa na uchafu na zilizotolewa na ushirikiano wa mbili (
        <bold>
         d
        </bold>
        ). Tathmini ya area under the curve (AUC) baada ya reactivation ya JQ1 ya kwanza (
        <bold>
         e
        </bold>
        ), ya pili (
        <bold>
         f
        </bold>
        ), na ya tatu (
        <bold>
         g
        </bold>
        ) kutoka kwa ndege zilizotambuliwa na uchafu (
        <italic>
         n
        </italic>
        = 8) na ndege zilizotambuliwa na uchafu na zilizotolewa na ushirikiano wa mbili, zote zilizotolewa na reactivation ya JQ1 mara mara 3 mara kwa wiki (
        <italic>
         n
        </italic>
        = 8).
        <italic>
         p
        </italic>
        values (unpaired one-tailed Mann–Whitney test) zinazohusishwa. Kila grafu ina thamani za ndege zilizotambuliwa na uchafu na thamani za kijani. AAV viral loads zinazohusishwa kwenye Supplemental Fig.
        <xref ref-type="supplementary-material" rid="MOESM1">
         9i
        </xref>
        . Data za kuzingatia zinazotolewa kama Source Data file.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-47940-y/41467_2024_47940_Fig6_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par14"/>
   </sec>
   <sec id="Sec8">
    <title>
     Uchambuzi wa meta kuhusu hatua ya AAV/meganuclease ya ufanisi wa vayiro ya HSV
    </title>
    <p id="Par15"/>
    <p id="Par16"/>
   </sec>
   <sec id="Sec9">
    <title>
     Unganisha ufanisi wa AAV-meganuclease
    </title>
    <p id="Par17">
     <fig id="Fig7" position="float">
      <label>
       Fig. 7
      </label>
      <caption xml:lang="en">
       <title>
        Simplification of the meganuclease/AAV regimen.
       </title>
       <p>
        <bold>
         a
        </bold>
        Mipimo wa muda wa ulemavu wa macho na usimamizi wa meganuclease.
        <bold>
         b
        </bold>
        ,
        <bold>
         c
        </bold>
        Matumizi ya HSV katika SCGs (
        <bold>
         b
        </bold>
        ; p &lt; 0.0001) na TGs (
        <bold>
         c
        </bold>
        ;
        <italic>
         p
        </italic>
        = 0.0046 kwa AAV9 na 0.0142 kwa 9-Dj/8-Rh10) kutoka kwa ndege zinazotokana na ulemavu na ndege zinazotokana na m4 iliyotolewa kwa njia ya retro-orbital (RO)) kwa injeksheni za 5 × 10
        <sup>
         11
        </sup>
        vg mara moja au mara matatu ya AAV9, -Dj/8 na -Rh10. Porsentagi ya ngatia ya matumizi ya HSV katika ndege zinazotolewa (
        <italic>
         n
        </italic>
        = 10 kwa kila kundi) mara kwa mara na ndege zinazotokana (
        <italic>
         n
        </italic>
        = 10) na tathmini ya takwimu (Ordinary one-way Anova, multiple comparisons with *
        <italic>
         p
        </italic>
        &lt; 0.05; **
        <italic>
         p
        </italic>
        &lt; 0.01, ****
        <italic>
         p
        </italic>
        &lt; 0.0001; ns: sio ya muhimu).
        <bold>
         d
        </bold>
        Foci za nyumba ya maji (ICF) katika sehemu za kibao kutoka kwa ndege zinazotokana na HSV (
        <italic>
         n
        </italic>
        = 10), au ndege zinazotolewa na m4 iliyotolewa kwa AAV mara moja au mara matatu ya AAV9, -Dj/8, na -Rh10 (
        <italic>
         n
        </italic>
        = 10 kwa kila kundi);
        <italic>
         p
        </italic>
        = 0.0009 kwa Rh10.
        <bold>
         e
        </bold>
        ,
        <bold>
         f
        </bold>
        Anuweli za ngatia ya axonopathy (
        <bold>
         e
        </bold>
        ) na nyumba ya maji (
        <bold>
         f
        </bold>
        ) katika TG kutoka kwa ndege zinazotokana na ulemavu (
        <italic>
         n
        </italic>
        = 3 TG) na ndege zinazotolewa na m4 iliyotolewa kwa AAV mara moja au mara matatu ya AAV9, -Dj/8 na -Rh10 (
        <italic>
         n
        </italic>
        = 3 TG kwa kila kundi) na tathmini ya takwimu (Ordinary one-way Anova, multiple comparisons with ns: sio ya muhimu; ***
        <italic>
         p
        </italic>
        &lt; 0.001). Kila grafu ina thamani za ndege zinazotokana na zinazotolewa na standard deviation. Matumizi ya AAV ya virus zinazotolewa zinazotunjazwa katika Supplemental Fig.
        <xref ref-type="supplementary-material" rid="MOESM1">
         9j–l
        </xref>
        . Source data zinazotolewa kama Source Data file.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-47940-y/41467_2024_47940_Fig7_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par18">
     <fig id="Fig8" position="float">
      <label>
       Fig. 8
      </label>
      <caption xml:lang="en">
       <title>
        Simplified meganuclease therapy decreases peripheral shedding in infected mice.
       </title>
       <p>
        <bold>
         a
        </bold>
        Mipimo wa muda wa ulemavu wa macho na usimamizi wa meganuclease na reactivations ya virus kwa JQ1.
        <bold>
         b
        </bold>
        Schematic ya meganuclease ya m4 ya kujifunza na ya si ya kujifunza.
        <bold>
         c
        </bold>
        -
        <bold>
         d
        </bold>
        , Matumizi ya HSV katika SCGs (
        <bold>
         c
        </bold>
        ; p &lt; 0.0001 kwa m4) na TGs (
        <bold>
         d
        </bold>
        ;
        <italic>
         p
        </italic>
        = 0.003 kwa m4) kutoka kwa ndege zinazotokana na ulemavu na ndege zinazotolewa na m4 ya kujifunza au ya si ya kujifunza (
        <italic>
         n
        </italic>
        = 10 kwa kila kundi). Porsentaji ya ngatia ya matumizi ya HSV katika ndege zinazotolewa mara kwa mara na ndege zinazotokana na tathmini ya takwimu (unpaired one-tailed Mann-Whitney test with *
        <italic>
         p
        </italic>
        &lt; 0.05; ****
        <italic>
         p
        </italic>
        &lt; 0.0001; ns: sio ya muhimu) zinazotolewa.
        <bold>
         e
        </bold>
        –
        <bold>
         g
        </bold>
        Titers ya virus katika swabs ya macho zinazotolewa kwa siku 1 hadi 3 baada ya kila reactivation ya JQ1 kutoka kwa ndege zinazotokana na ulemavu (
        <bold>
         e
        </bold>
        ) na ndege zinazotolewa na m4 ya kujifunza (
        <bold>
         f
        </bold>
        ) au ya si ya kujifunza (
        <bold>
         g
        </bold>
        ).
        <bold>
         h
        </bold>
        ,
        <bold>
         i
        </bold>
        Analysis ya area under the curve (AUC) ya virus shedding baada ya kwanza (
        <bold>
         h
        </bold>
        ), na pili (
        <bold>
         i
        </bold>
        ) reactivation ya JQ1 kutoka kwa ndege zinazotokana na ulemavu na ndege zinazotolewa na m4 ya kujifunza au ya si ya kujifunza (
        <italic>
         n
        </italic>
        = 10 kwa kila kundi).
        <italic>
         p
        </italic>
        values (unpaired one-tailed Mann–Whitney test) zinazotolewa.
        <bold>
         j
        </bold>
        Foci za nyumba ya maji (ICF) katika sehemu za kibao kutoka kwa ndege zinazotokana na HSV, ndege zinazotolewa na m4 ya kujifunza au ya si ya kujifunza (
        <italic>
         n
        </italic>
        = 10 kwa kila kundi);
        <italic>
         p
        </italic>
        = 0.0234 kwa m4.
        <bold>
         k
        </bold>
        ,
        <bold>
         l
        </bold>
        Anuweli za ngatia ya axonopathy (
        <bold>
         k
        </bold>
        ;
        <italic>
         p
        </italic>
        = 0.0007 kwa m4) na nyumba ya maji (
        <bold>
         l
        </bold>
        ) katika TG kutoka kwa ndege zinazotokana na HSV, ndege zinazotolewa na m4 ya kujifunza au ya si ya kujifunza (
        <italic>
         n
        </italic>
        = 10 kwa kila kundi) na tathmini ya takwimu (Ordinary one-way Anova, multiple comparisons with ns: sio ya muhimu; *
        <italic>
         p
        </italic>
        &lt; 0.05; ***
        <italic>
         p
        </italic>
        &lt; 0.001). Kila grafu ina thamani za ndege zinazotokana na zinazotolewa na standard deviation. Matumizi ya AAV ya virus zinazotolewa zinazotunjazwa katika Supplemental Fig.
        <xref ref-type="supplementary-material" rid="MOESM1">
         9m–o
        </xref>
        . Source data zinazotolewa kama Source Data file.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-47940-y/41467_2024_47940_Fig8_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec10">
    <title>
     Ukawaida wa ufanisi wa meganuclease hupunguza usalama
    </title>
    <p id="Par19"/>
   </sec>
  </sec>
  <sec id="Sec11" sec-type="discussion">
   <title>
    Mazungumzo
   </title>
   <p id="Par20"/>
   <p id="Par21"/>
   <p id="Par22"/>
   <p id="Par23"/>
   <p id="Par24">
    Mfano muhimu mwingine katika utafiti wetu ni kwamba meganucleases zinazohifadhiwa na AAV zinaweza kuingia marafiki na kuhariri HSV ndani ya DRG, mahali pa uhalifu wa HSV katika afya ya kijamii. Tumeonekana mara nyingi kuna tofauti kubwa katika kurejelea viwango vya virus ya HSV katika SCG (ambayo ni ganglia za autonomic; mara nyingi ~90% kurejelea) mara kwa TG (ganglia za sensory; mara nyingi ~50-60% kurejelea). Hii ilipata uweko kwamba DRG (pia ni ganglia za sensory) ingeweza pia kuchukuliwa na viwango visivyo vya kurejelea kwa kutosha. Hata hivyo, hariri ya genome za HSV zinazouhalifu ilipatikana kuwa na ufanisi mkubwa ndani ya DRG (97% kurejelea), inayamshuhudia kwamba tofauti za ufanisi hawana uhusiano na aina ya ganglion (sensory
    <italic>
     vs
    </italic>
    <sup/>
    . autonomic). Sasa tumechagua mawazo ya kwamba ufanisi wa AAV transduction katika ganglia zingine zinazohusika zinajulikana kwa kutosha na ufanisi wa kuburudika wa barabara ya damu/ganglionic kwa kila aina ya ganglion, na tumeanza siri za utafiti kubainisha maswala hii.
   </p>
   <p id="Par25">
    Mhadhara moja ya kazi yetu ni kwamba viwango vya HSV-1 vinavyovutia meganucleases vinavyotumika katika utafiti huu hawana uhakika katika HSV-2. Kwa hiyo tumezitumia majaribio ya uchafu kwa HSV-1, ili kujulikisha kwamba hakuna mawazo ya kuchukuliwa katika uchafuzi wa afya ya kijamii
    <italic>
     vs
    </italic>
    <sup/>
    . orofacial; hii ni, marafiki zinazouhalifu katika mahali yote mara nyingi zinaweza kupata AAV vectors kwa kutosha na pia hariri ya genome za HSV zinazouhalifu kwa meganucleases. Tumeamini kwamba uchafuzi wa kifupi wa HSV-1 kwa afya ya kijamii si matokeo ya kawaida – zaidi ya nusu ya mawazo mpya ya herpes ya kijamii katika Marekani sasa huwasababishwa na HSV-1
    <sup>
     <xref ref-type="bibr" rid="CR27">
      27
     </xref>
    </sup>
    . Hata hivyo, tumeamini kwa kawaida muhimu ya HSV-2 kama chaguo, na kazi ya sasa katika maktaba yetu inafokusia kujenga meganucleases za anti-HSV-2 na kuchanganisha katika mice na modele za uchafuzi zingine. Tumeamini zaidi katika kuchukua viwango vya kirembe katika HSV-2, ambavyo matokeo yetu hapa yanashuhudia kwamba yanaweza kusimamia hariri ya kifupi ya nuclease moja, na tumeamini kwamba viwango vya kirembe au vya kirembe vya mara nyingi yanaweza kuchukuliwa kwa hariri ya gene kufanya kazi kuchukua virus zingine.
   </p>
   <p id="Par26"/>
  </sec>
  <sec id="Sec12" sec-type="methods">
   <title>
    Viwango
   </title>
   <sec id="Sec13">
    <title>
     Mice
    </title>
    <p id="Par27"/>
    <p id="Par28"/>
   </sec>
   <sec id="Sec14">
    <title>
     Uchafu wa macho na HSV
    </title>
    <p id="Par29"/>
   </sec>
   <sec id="Sec15">
    <title>
     Uchafu wa kijamii na HSV
    </title>
    <p id="Par30"/>
   </sec>
   <sec id="Sec16">
    <title>
     Uingizaji wa AAV
    </title>
    <p id="Par31"/>
   </sec>
   <sec id="Sec17">
    <title>
     Ruhusa ya uchunguzi
    </title>
    <p id="Par32"/>
   </sec>
   <sec id="Sec18">
    <title>
     Unganisho wa vayiro ya HSV
    </title>
    <p id="Par33"/>
   </sec>
   <sec id="Sec19">
    <title>
     Cells, herpes simplex viruses, na AAV stocks
    </title>
    <p id="Par34">
     Mimba HEK293 na Vero (ATCC # CCL-81) zilizotengenezwa katika madhania ya Dubelcco’s modified Eagle ya kusongezwa kwa 10% serum ya mbwa mchoto. Strain ya HSV-1
     <italic>
      syn
     </italic>
     17 + (yaliyotoeleweka kwa Dr. Sawtell) ilitengenezwa na ilipatikana kwa nyaraka za Vero
     <sup>
      <xref ref-type="bibr" rid="CR41">
       41
      </xref>
     </sup>
     .
    </p>
    <p id="Par35">
     Uhusiano na AAV na kipimo chake. Mimba ya AAV ya plasmids pscAAV-CBh-m5, pscAAV-CBh-m8, pscAAV-CBh-m4, pscAAV-CBh -m4i na pscAAV-E/CamKII-m4 zilizotumika kusongeza mimba za AAV katika utafiti huu (Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S12
     </xref>
     ). Mimba zote za AAV zilizotengenezwa kutoka kwa HEK293 zilizotolewa na madhania ya kultur yaliyotengenezwa na Viral Vector Core ya Wellstone Muscular Dystrophy Specialized Research Center (Seattle). Mimba za AAV zilizotengenezwa kwa njia ya PEG-precipitation ya virus kutoka kwa lysates ya nyaraka na madhania ya kultur, kisha zilizoseparatiwa kwa njia ya iodixanol gradient na zilizorudishiwa kwenye PBS kwa kutumia Amicon Ultra-15 column (EMD Millipore). Mimba za AAV zilizorudishiwa na zilizohifadhiwa kwenye −80C. Mimba zote za AAV zilizokipima kwa njia ya qPCR kwa kutumia primers/probe ya AAV ITR, kwa kutumia plasmid DNA ya linearized kama standard, kulingana na njia ya Aurnhammer et al.
     <sup>
      <xref ref-type="bibr" rid="CR42">
       42
      </xref>
      ,
      <xref ref-type="bibr" rid="CR43">
       43
      </xref>
      <xref ref-type="bibr" rid="CR44">
       44
      </xref>
     </sup>
     . Mimba za AAV zilizotumika DNase I na Proteinase K kabla ya kipimo.
    </p>
   </sec>
   <sec id="Sec20">
    <title>
     Viwango vya mizigo ya vayiro katika viungo
    </title>
    <p id="Par36">
     DNA ya jumla ya genomu ilizotolewa kutoka kwa viungo vya ganglionic kwa kutumia DNeasy Blood and tissues kit (Qiagen, Germantown, MD) kulingana na protokoli ya mshengaji. Genomu za virus zilizokipima kwa njia ya ddPCR katika sampuli za DNA ya viungo kwa kutumia set ya AAV ITR primer/probe kwa AAV, na set ya gB primer/probe kwa HSV kama ilivyoelewea kwa mara nyingine
     <sup>
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
     </sup>
     . Namba za nyaraka katika viungo zilizokipima kwa njia ya ddPCR kwa kutumia set ya RPP30 primer/probe ya specific ya paka: Forward 5′-GGCGTTCGCAGATTTGGA, Reverse 5′- TCCCAGGTGAGCAGCAGTCT, probe 5′-ACCTGAAGGCTCTGCGCGGACTC. Katika baadhi ya viungo vya ganglionic vya kawaida, sampuli vya kawaida vilizostahiliwa kwa AAV genomes, hata hivyo marufuku yao yalikuwa mara nyingi &gt;2-3 logs chache zaidi kuliko katika viungo vya ganglionic vya nyaraka vilivyopata AAV. Tunazoweza kutoa sababu hii kwa uchafu wa marufuku ya sampuli za viungo vya kawaida. Marufuku ya AAV ya viungo vya ganglionic kwa utafiti uliyotolewa katika Figs.
     <xref ref-type="fig" rid="Fig1">
      1
     </xref>
     –
     <xref ref-type="fig" rid="Fig3">
      3
     </xref>
     na
     <xref ref-type="fig" rid="Fig5">
      5
     </xref>
     –
     <xref ref-type="fig" rid="Fig8">
      8
     </xref>
     zinazostahiliwa katika Supplemental Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      9
     </xref>
     na zinazostahiliwa katika Fig.
     <xref ref-type="fig" rid="Fig9">
      9
     </xref>
     zinazostahiliwa katika Supplemental fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      10
     </xref>
     <sup/>
     . Tathmini ya tathmini iliyofanyika kwa kutumia GraphPad Prism version 9.4.1. Tathmini ya kila set ya data iliyotolewa katika legenda za picha.
    </p>
   </sec>
   <sec id="Sec21">
    <title>
     Viwango vya HSV katika swab za macho
    </title>
    <p id="Par37">
     Sampuli za swab zilizotolewa kwenye vials zinazohisi 1 ml ya buffer ya digestion (KCL, Tris HCl pH8.0, EDTA, Igepal CA-630). DNA ilizotolewa kutoka kwa 200 ml ya buffer ya digestion kwa kutumia QiaAmp 96 DNA Blood Kits (Qiagen, Germantown, MD) na ilizorudishiwa kwenye 100 ml AE buffer (Qiagen). Kisha, 10 ml ya DNA ilizotumika kusambaza 30 ml real-time Taqman quantitative PCR reactions. Primers na probes zilizoelewea kama ilivyoelewea kwa mara nyingine
     <sup>
      <xref ref-type="bibr" rid="CR45">
       45
      </xref>
     </sup>
     . QuantiTect multiplex PCR mix (Qiagen) ilizotumika kwa PCR assays. Mawasilisho ya PCR yalikuwa kama ifuatayo: 1 mada kwenye 50 °C kwa dakika 2, 1 mada kwenye 95 °C kwa dakika 15, na 45 mada ya 94 °C kwa dakika 1 na 60 °C kwa dakika 1. Exo internal control ilizotolewa kwenye kila mawasilisho ya PCR kwa kuzungumza uharibifu. Natafsi ya hasi iliyotolewa tu ikiwa internal control ilikuwa hasi na cycle threshold (CT) ndani ya 3 mada ya Exo CT ya no template controls.
    </p>
   </sec>
   <sec id="Sec22">
    <title>
     Uonyeshaji wa Western blot
    </title>
    <p id="Par38">
     Lysates ya viungo vilizotolewa kutoka kwa 1 TG kwa kila nyaraka iliyotolewa kwenye 200 μl RIPA buffer (PIERCE, Thermo Scientific) na protease inhibitor cocktail (Roche) na vilizotengenezwa kwa sonication kwenye barafu. Thirteen microliters ya lysates ya viungo vilizotolewa kwenye 4-12% NuPAGE gel, vilizotumika kwenye membrane ya nitrocellulose na vilizotumika kwa m4 expression kwa kutumia rabbit anti-HA antibody (1:1000 mAb clone C29F, Cell signaling) na β-actin (1: 1000 mAb clone13E5, cell signaling) kwa kuzungumza protein loading. Membrane hybridization na detection vilizofanyika kwa kutumia PIERCE Fast Western blotting kit Super signal, West pico Rabbit (Thermo Scientific) kulingana na protokoli ya mshengaji na vilizopicha kwa kutumia ChemiDoc Imaging system (BIO-RAD).
    </p>
   </sec>
   <sec id="Sec23">
    <title>
     Unganisho wa inflammatory cell foci
    </title>
    <p id="Par39">
     Mifumo ya kibao ya mwili ilikuwa zimeingizwa kwenye paraffin, zimegawanyika na zimebadilishwa na H&amp;E kwa madhumuni ya histopathology ya maoni ya majaribio ya Fred Hutchinson Cancer Center. ICF iliyohisiwa na mtazamaji wa kushindana na iliyotolewa kama namba ya ICF kwa eneo la kifupi ambao iliyotathminiwa kwa kutumia Fiji
     <sup>
      <xref ref-type="bibr" rid="CR46">
       46
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec24">
    <title>
     Ugundishaji wa mabadiliko ya neurons katika trigeminal ganglia
    </title>
    <p id="Par40">
     Mifumo ya ganglion ya trigeminal ilikuwa zimeingizwa kwenye paraffin, zimegawanyika, na zimebadilishwa na H&amp;E kwa madhumuni ya histopathology ya maoni ya majaribio ya Fred Hutchinson Cancer Center. Mabadiliko ya mikoa iliyotathminiwa kuhusu uhalifu na kwa madhumuni wa veterinary pathologist kwa kutumia mfumo wa thamani standard ambao 0 = hakuna mabadiliko yanayohitaji, 1 = yanayohitaji kidogo, 2 = yanayohitaji kidogo, 3 = yanayohitaji kifupi, na 4 = yanayohitaji kifupi sana.
    </p>
   </sec>
   <sec id="Sec25">
    <title>
     Uchambuzi wa viwango
    </title>
    <p id="Par41">
     Uchanganuzi wa tathminiwa kwa kila majaribio iliyofanyika kwa kutumia GraphPad Prism version 9.4.1 na R. Vyanzo vilikuwa vilivyotolewa kwa pande mbili na p-values vinavyo ndogo zaidi ya 0.05 vilivyohitaji. Tathmini ambavyo vilivyotumika kwa kila tathmini iliyotolewa kwenye legenda ya picha inayohusiana.
    </p>
    <p id="Par42">
     Uchanganuzi wa meta iliyofanyika kwenye data iliyolengwa kwa majaribio yote (Figs.
     <xref ref-type="fig" rid="Fig1">
      1
     </xref>
     –
     <xref ref-type="fig" rid="Fig6">
      6
     </xref>
     ). Kusubiri kuhusu kama ndege zinazotolewa na AAV/MN zinazotolea virus zaidi kidogo kuliko ndege zinazotolewa na majaribio na kama kifupi cha kutolea virus kuchunguza na muda wa tathmini wa meganuclease, tulitumia vyanzo vya linear mixed models (GLMM) vyanavyosema kuhusu uwezekano wa kutolea virus (kutokana na viral shedding inayotolewa kama AUC &gt; 0) kama funksi ya muda wa tathmini na dozi iliyotumika kama vyanzo vilivyotolewa, wakati kuchunguza majaribio. Vyanzo vilivyohusiana na ndege vilivyotolewa katika mada ili kuhakikisha uhusiano wa ndege kati ya mazungumzo. Tulitumia pia vyanzo vilivyotolewa kati ya dozi na muda ili kuchunguza kama mabadiliko ya uwezekano wa kutolea virus kulingana na muda ilikuwa yanayohitaji kwa dozi (kwa ujumla, kama ilikuwa yanayokidhi kwa haraka zaidi kwa dozi). Uhusiano wa kutolea virus na vyanzo vilivyotolewa (dozi, muda ya tathmini) viliratibiwa kama nisaba za uwezekano (OR). Uhusiano wa uwezekano wa kutolea virus na dozi, muda ya tathmini, na vyanzo vilivyotolewa vilichukuliwa kwa kutumia vyanzo vya Wald vya pande mbili.
    </p>
    <p id="Par43">
     Kusubiri kuhusu uhusiano wa kifupi cha kutolea virus na dozi ya tathmini na muda, tulitumia vyanzo vya linear mixed models (LMM) vyanavyosema kuhusu log10-transformed AUC kama funksi ya dozi ya tathmini na muda, vilivyotolewa kama vyanzo vilivyotolewa, wakati kuchunguza majaribio. Mada iliyotolewa kati ya dozi na muda ya tathmini ili kuchunguza kama mabadiliko ya AUC kulingana na muda ilikuwa yanayohitaji kwa dozi (kwa ujumla, kama log10-transformed AUC ilikuwa yanayokidhi kwa haraka zaidi kwa dozi). Vyanzo vilivyohusiana na ndege vilivyotolewa katika mada ili kuhakikisha uhusiano wa ndege kati ya mazungumzo. Maana ya vyanzo vilivyotolewa vilichukuliwa kwa kutumia estimator ya sandwichi ya kibinafsi. Uhusiano wa kutolea virus na vyanzo vilivyotolewa (dozi, muda ya tathmini) viliratibiwa kama nisaba za uwezekano (OR). Uhusiano wa log10-transformed AUC na dozi, muda ya tathmini, na vyanzo vilivyotolewa vilichukuliwa kwa kutumia vyanzo vya Wald. Vyanzo vyote vilivyotolewa vilichukuliwa pia vyanzo vilivyotolewa vilivyotolewa kati ya dozi ya kawaida na kawaida ya dozi ili kuchunguza uhusiano wa kawaida na kawaida ya dozi na kawaida ya dozi na kawaida ya dozi.
    </p>
   </sec>
   <sec id="Sec26">
    <title>
     Reporting summary
    </title>
    <p id="Par44">
     Uzoefu zaidi kuhusu mifano ya utafiti yamepatikana kwenye
     <xref ref-type="supplementary-material" rid="MOESM3">
      Nature Portfolio Reporting Summary
     </xref>
     iliyolinkwa kwenye makala hii.
    </p>
   </sec>
  </sec>
 </body>
 <back>
  <ack>
   <title>
    Acknowledgements
   </title>
   <p>
    Nasikitika kwa Cellectis (Paris, France) kwa uendelezaji wa awali wa meganucleases m4, m5, na m8, pia kwa Philippe Duchateau na Roman Galetto (Cellectis) kwa majadiliano yanayofaa. Kazi hii imeundwa kwa msaada wa grant ya National Institutes of Health R01AI132599 (KRJ), Caladan Foundation (KRJ), grant ya National Institutes of Health 5P50AR065139 (Viral Vector Core of the Wellstone Muscular Dystrophy Specialized Research Center, Seattle), National Institutes of Health / National Cancer Institutes, Cancer Center Support Grant P30 CA015704 (Fred Hutchinson Cancer Center Shared Resources Division), huduma zinazotokea kutoka kwa Kenneth Hill Foundation, Krieger Family Trust, Tiny Foundation, na zaidi ya 2000 wadono watafsiri.
   </p>
  </ack>
  <sec sec-type="author-contribution">
   <title>
    Author contributions
   </title>
   <p>
    Umaarufu: K.R.J., M.A., D.S., D.E.S. na O.H. Uchunguzi: M.A., A.K.H., D.E.S., L.M.K., M.A.L., L.S., T.K.S. na O.H. Uhusiano wa fedha: K.J.R., M.A. na D.S. Uwekezaji: K.R.J., M.A., D.S. na M.L.H. Uandishi – maelezo ya awali: M.A., K.R.J. na O.H. Uandishi – ushindaji &amp; uharakati: M.A., K.R.J., D.S. na O.H.
   </p>
  </sec>
  <sec sec-type="peer-review">
   <title>
    Uchambuzi wa wanaomuathiri
   </title>
   <sec id="FPar1">
    <title>
     Uchambuzi wa wanaomuathiri
    </title>
    <p id="Par45">
     <italic>
      Nature Communications
     </italic>
     thanks Joseph Glorioso, Paul Kinchington and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.
    </p>
   </sec>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Uradhi wa data
   </title>
   <p>
    All data generated are provided in the main text, the supplementary materials or the Source Data file. Meganuclease sequences are Cellectis proprietary information and material. Source data is provided with this paper.
    <xref ref-type="sec" rid="Sec28">
     Source data
    </xref>
    are provided with this paper.
   </p>
  </sec>
  <sec sec-type="ethics-statement">
   <sec id="FPar2" sec-type="COI-statement">
    <title>
     Ushindani wa kusimamia
    </title>
    <p id="Par46">
     K.R.J. is a founder and holds equity in Caladan Therapeutics, is a paid advisor and holds equity in Excision Biosciences, participates in sponsored research agreements with Excision Biosciences and Emendo Biotherapeutics, and is co-inventor of International Patent Application No. PCT/US2022/013757 and U.S. Provisional Application No. 63/503,541 held by Fred Hutch for the treatment of HSV-1 and HSV-2 using meganucleases. There are no restrictions on publication of data. M.A. and D.S. have sponsored research agreements with Excision Biosciences. The remaining authors declare no conflict of interest.
    </p>
   </sec>
  </sec>
  <ref-list id="Bib1">
   <title>
    Viungo vya kutatua
   </title>
   <ref-list>
    <ref id="CR1">
     <label>
      1.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Schiffer
        </surname>
        <given-names>
         JT
        </given-names>
       </name>
       <name>
        <surname>
         Corey
        </surname>
        <given-names>
         L
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       New concepts in understanding genital herpes
      </article-title>
      <source>
       Curr. Infect. Dis. Rep.
      </source>
      <year>
       2009
      </year>
      <volume>
       11
      </volume>
      <fpage>
       457
      </fpage>
      <lpage>
       464
      </lpage>
      <pub-id pub-id-type="pmid">
       19857385
      </pub-id>
      <pub-id pub-id-type="pmcid">
       2804398
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1007/s11908-009-0066-7
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR2">
     <label>
      2.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Corey
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Once-daily valacyclovir to reduce the risk of transmission of genital herpes
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2004
      </year>
      <volume>
       350
      </volume>
      <fpage>
       11
      </fpage>
      <lpage>
       20
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD2cXhtFGitg%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       14702423
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa035144
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR3">
     <label>
      3.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Gupta
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract
      </article-title>
      <source>
       J. Infect. Dis.
      </source>
      <year>
       2004
      </year>
      <volume>
       190
      </volume>
      <fpage>
       1374
      </fpage>
      <lpage>
       1381
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD2cXps1amt7s%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       15378428
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1086/424519
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR4">
     <label>
      4.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Fife
        </surname>
        <given-names>
         KH
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial
      </article-title>
      <source>
       Mayo Clin Proc.
      </source>
      <year>
       2006
      </year>
      <volume>
       81
      </volume>
      <fpage>
       1321
      </fpage>
      <lpage>
       1327
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD28XhtFert7nL
      </pub-id>
      <pub-id pub-id-type="pmid">
       17036557
      </pub-id>
      <pub-id pub-id-type="doi">
       10.4065/81.10.1321
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR5">
     <label>
      5.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Mertz
        </surname>
        <given-names>
         GJ
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial
      </article-title>
      <source>
       JAMA
      </source>
      <year>
       1988
      </year>
      <volume>
       260
      </volume>
      <fpage>
       201
      </fpage>
      <lpage>
       206
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DyaL1c3lvFCmsQ%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       3290517
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1001/jama.1988.03410020067030
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR6">
     <label>
      6.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wald
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <name>
        <surname>
         Zeh
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Barnum
        </surname>
        <given-names>
         G
        </given-names>
       </name>
       <name>
        <surname>
         Davis
        </surname>
        <given-names>
         LG
        </given-names>
       </name>
       <name>
        <surname>
         Corey
        </surname>
        <given-names>
         L
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir
      </article-title>
      <source>
       Ann. Intern. Med.
      </source>
      <year>
       1996
      </year>
      <volume>
       124
      </volume>
      <fpage>
       8
      </fpage>
      <lpage>
       15,
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DyaK28XhtFKls78%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       7503497
      </pub-id>
      <pub-id pub-id-type="doi">
       10.7326/0003-4819-124-1_Part_1-199601010-00002
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR7">
     <label>
      7.
     </label>
     <mixed-citation publication-type="other">
      Aubert, M. et al. In vivo disruption of latent HSV by designer endonuclease therapy.
      <italic>
       JCI Insight
      </italic>
      <ext-link ext-link-type="doi" xlink:href="10.1172/jci.insight.88468">
       https://doi.org/10.1172/jci.insight.88468
      </ext-link>
      (2016).
     </mixed-citation>
    </ref>
    <ref id="CR8">
     <label>
      8.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Aubert
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Gene editing and elimination of latent herpes simplex virus in vivo
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2020
      </year>
      <volume>
       11
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2020NatCo..11.4148A
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhs1CktLrM
      </pub-id>
      <pub-id pub-id-type="pmid">
       32811834
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7435201
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-020-17936-5
      </pub-id>
      <elocation-id>
       4148
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR9">
     <label>
      9.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Oseso
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <name>
        <surname>
         Magaret
        </surname>
        <given-names>
         AS
        </given-names>
       </name>
       <name>
        <surname>
         Jerome
        </surname>
        <given-names>
         KR
        </given-names>
       </name>
       <name>
        <surname>
         Fox
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Wald
        </surname>
        <given-names>
         A
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Attitudes and willingness to assume risk of experimental therapy to eradicate genital herpes simplex virus infection
      </article-title>
      <source>
       Sex Transm. Dis.
      </source>
      <year>
       2016
      </year>
      <volume>
       43
      </volume>
      <fpage>
       566
      </fpage>
      <lpage>
       571
      </lpage>
      <pub-id pub-id-type="pmid">
       27513383
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4985010
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1097/OLQ.0000000000000493
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR10">
     <label>
      10.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Jacques
        </surname>
        <given-names>
         SJ
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       AAV8(gfp) preferentially targets large diameter dorsal root ganglion neurones after both intra-dorsal root ganglion and intrathecal injection
      </article-title>
      <source>
       Mol Cell Neurosci.
      </source>
      <year>
       2012
      </year>
      <volume>
       49
      </volume>
      <fpage>
       464
      </fpage>
      <lpage>
       474
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC38XmsVert7w%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       22425560
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.mcn.2012.03.002
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR11">
     <label>
      11.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Samaranch
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates
      </article-title>
      <source>
       Hum. Gene Ther.
      </source>
      <year>
       2013
      </year>
      <volume>
       24
      </volume>
      <fpage>
       526
      </fpage>
      <lpage>
       532
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC3sXns1ahs74%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       23517473
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3655626
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1089/hum.2013.005
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR12">
     <label>
      12.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Grosse
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Meganuclease-mediated inhibition of HSV1 infection in cultured cells
      </article-title>
      <source>
       Mol. Ther.
      </source>
      <year>
       2011
      </year>
      <volume>
       19
      </volume>
      <fpage>
       694
      </fpage>
      <lpage>
       702
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC3MXjslWrtQ%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       21224832
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3070101
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/mt.2010.302
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR13">
     <label>
      13.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Parr
        </surname>
        <given-names>
         MB
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2
      </article-title>
      <source>
       Lab Invest.
      </source>
      <year>
       1994
      </year>
      <volume>
       70
      </volume>
      <fpage>
       369
      </fpage>
      <lpage>
       380
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DyaK2c7psVyktA%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       8145530
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR14">
     <label>
      14.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Alfonso-Dunn
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Transcriptional elongation of HSV immediate early genes by the super elongation complex drives lytic infection and reactivation from latency
      </article-title>
      <source>
       Cell Host Microbe
      </source>
      <year>
       2017
      </year>
      <volume>
       21
      </volume>
      <fpage>
       507
      </fpage>
      <lpage>
       517.e505
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC2sXmtFOitbc%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       28407486
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5997188
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.chom.2017.03.007
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR15">
     <label>
      15.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sawtell
        </surname>
        <given-names>
         NM
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Detection and quantification of the rare latently infected cell undergoing herpes simplex virus transcriptional activation in the nervous system in vivo
      </article-title>
      <source>
       Methods Mol. Biol.
      </source>
      <year>
       2005
      </year>
      <volume>
       292
      </volume>
      <fpage>
       57
      </fpage>
      <lpage>
       72
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD2MXjt1agug%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       15507701
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR16">
     <label>
      16.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Schiffer
        </surname>
        <given-names>
         JT
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model
      </article-title>
      <source>
       Sci. Transl. Med.
      </source>
      <year>
       2009
      </year>
      <volume>
       1
      </volume>
      <fpage>
       7ra16
      </fpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2009oja..book.....S
      </pub-id>
      <pub-id pub-id-type="pmid">
       20161655
      </pub-id>
      <pub-id pub-id-type="pmcid">
       2818652
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1126/scitranslmed.3000193
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR17">
     <label>
      17.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hioki
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Efficient gene transduction of neurons by lentivirus with enhanced neuron-specific promoters
      </article-title>
      <source>
       Gene Ther.
      </source>
      <year>
       2007
      </year>
      <volume>
       14
      </volume>
      <fpage>
       872
      </fpage>
      <lpage>
       882
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD2sXltlejs7o%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       17361216
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/sj.gt.3302924
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR18">
     <label>
      18.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kollias
        </surname>
        <given-names>
         CM
        </given-names>
       </name>
       <name>
        <surname>
         Huneke
        </surname>
        <given-names>
         RB
        </given-names>
       </name>
       <name>
        <surname>
         Wigdahl
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <name>
        <surname>
         Jennings
        </surname>
        <given-names>
         SR
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Animal models of herpes simplex virus immunity and pathogenesis
      </article-title>
      <source>
       J. Neurovirol.
      </source>
      <year>
       2015
      </year>
      <volume>
       21
      </volume>
      <fpage>
       8
      </fpage>
      <lpage>
       23
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC2cXhvFagu77K
      </pub-id>
      <pub-id pub-id-type="pmid">
       25388226
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1007/s13365-014-0302-2
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR19">
     <label>
      19.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hill
        </surname>
        <given-names>
         TJ
        </given-names>
       </name>
       <name>
        <surname>
         Shimeld
        </surname>
        <given-names>
         C
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Models of recurrent infection with HSV in the skin and eye of the mouse
      </article-title>
      <source>
       Methods Mol. Med.
      </source>
      <year>
       1998
      </year>
      <volume>
       10
      </volume>
      <fpage>
       273
      </fpage>
      <lpage>
       289,
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC3M3kt1alsQ%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       21374236
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR20">
     <label>
      20.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Cook
        </surname>
        <given-names>
         SD
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Ocular herpes simplex virus reactivation in mice latently infected with latency-associated transcript mutants
      </article-title>
      <source>
       Invest. Ophthalmol. Vis. Sci.
      </source>
      <year>
       1991
      </year>
      <volume>
       32
      </volume>
      <fpage>
       1558
      </fpage>
      <lpage>
       1561
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DyaK3M3gtFShug%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       1849874
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR21">
     <label>
      21.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sawtell
        </surname>
        <given-names>
         NM
        </given-names>
       </name>
       <name>
        <surname>
         Thompson
        </surname>
        <given-names>
         RL
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia
      </article-title>
      <source>
       J. Virol.
      </source>
      <year>
       1992
      </year>
      <volume>
       66
      </volume>
      <fpage>
       2150
      </fpage>
      <lpage>
       2156
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DyaK387psVCmsg%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       1312625
      </pub-id>
      <pub-id pub-id-type="pmcid">
       289007
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1128/jvi.66.4.2150-2156.1992
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR22">
     <label>
      22.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Laycock
        </surname>
        <given-names>
         KA
        </given-names>
       </name>
       <name>
        <surname>
         Lee
        </surname>
        <given-names>
         SF
        </given-names>
       </name>
       <name>
        <surname>
         Brady
        </surname>
        <given-names>
         RH
        </given-names>
       </name>
       <name>
        <surname>
         Pepose
        </surname>
        <given-names>
         JS
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Characterization of a murine model of recurrent herpes simplex viral keratitis induced by ultraviolet B radiation
      </article-title>
      <source>
       Invest. Ophthalmol. Vis. Sci.
      </source>
      <year>
       1991
      </year>
      <volume>
       32
      </volume>
      <fpage>
       2741
      </fpage>
      <lpage>
       2746
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DyaK3MzntlWitw%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       1654309
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR23">
     <label>
      23.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Alamer
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <name>
        <surname>
         Zhong
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <name>
        <surname>
         Hajnik
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <name>
        <surname>
         Soong
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <name>
        <surname>
         Hu
        </surname>
        <given-names>
         H
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Modulation of BRD4 in HIV epigenetic regulation: implications for finding an HIV cure
      </article-title>
      <source>
       Retrovirology
      </source>
      <year>
       2021
      </year>
      <volume>
       18
      </volume>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXkvFKiuro%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33413475
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7792063
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1186/s12977-020-00547-9
      </pub-id>
      <elocation-id>
       3
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR24">
     <label>
      24.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ramchandani
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Herpes simplex virus type 1 shedding in tears and nasal and oral mucosa of healthy adults
      </article-title>
      <source>
       Sex Transm. Dis.
      </source>
      <year>
       2016
      </year>
      <volume>
       43
      </volume>
      <fpage>
       756
      </fpage>
      <lpage>
       760
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC28XhvVGqsb3I
      </pub-id>
      <pub-id pub-id-type="pmid">
       27835628
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5117635
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1097/OLQ.0000000000000522
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR25">
     <label>
      25.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Schiffer
        </surname>
        <given-names>
         JT
        </given-names>
       </name>
       <name>
        <surname>
         Mayer
        </surname>
        <given-names>
         BT
        </given-names>
       </name>
       <name>
        <surname>
         Fong
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
       <name>
        <surname>
         Swan
        </surname>
        <given-names>
         DA
        </given-names>
       </name>
       <name>
        <surname>
         Wald
        </surname>
        <given-names>
         A
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding
      </article-title>
      <source>
       J. R. Soc. Interface
      </source>
      <year>
       2014
      </year>
      <volume>
       11
      </volume>
      <fpage>
       20140160
      </fpage>
      <pub-id pub-id-type="pmid">
       24671939
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4006256
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1098/rsif.2014.0160
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR26">
     <label>
      26.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Schiffer
        </surname>
        <given-names>
         JT
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract
      </article-title>
      <source>
       Elife
      </source>
      <year>
       2013
      </year>
      <volume>
       2
      </volume>
      <pub-id pub-id-type="pmid">
       23606943
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3629793
      </pub-id>
      <pub-id pub-id-type="doi">
       10.7554/eLife.00288
      </pub-id>
      <elocation-id>
       e00288
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR27">
     <label>
      27.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ryder
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <name>
        <surname>
         Jin
        </surname>
        <given-names>
         F
        </given-names>
       </name>
       <name>
        <surname>
         McNulty
        </surname>
        <given-names>
         AM
        </given-names>
       </name>
       <name>
        <surname>
         Grulich
        </surname>
        <given-names>
         AE
        </given-names>
       </name>
       <name>
        <surname>
         Donovan
        </surname>
        <given-names>
         B
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992-2006
      </article-title>
      <source>
       Sex Transm. Infect.
      </source>
      <year>
       2009
      </year>
      <volume>
       85
      </volume>
      <fpage>
       416
      </fpage>
      <lpage>
       419
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BD1Mnos1OqtQ%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       19273479
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1136/sti.2008.033902
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR28">
     <label>
      28.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bulcha
        </surname>
        <given-names>
         JT
        </given-names>
       </name>
       <name>
        <surname>
         Wang
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
       <name>
        <surname>
         Ma
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <name>
        <surname>
         Tai
        </surname>
        <given-names>
         PWL
        </given-names>
       </name>
       <name>
        <surname>
         Gao
        </surname>
        <given-names>
         G
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Viral vector platforms within the gene therapy landscape
      </article-title>
      <source>
       Signal Transduct. Target. Ther.
      </source>
      <year>
       2021
      </year>
      <volume>
       6
      </volume>
      <fpage>
       53
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhtVOmsL7N
      </pub-id>
      <pub-id pub-id-type="pmid">
       33558455
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7868676
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41392-021-00487-6
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR29">
     <label>
      29.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hinderer
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN
      </article-title>
      <source>
       Hum. Gene Ther.
      </source>
      <year>
       2018
      </year>
      <volume>
       29
      </volume>
      <fpage>
       285
      </fpage>
      <lpage>
       298
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXnsVKnt7o%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       29378426
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5865262
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1089/hum.2018.015
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR30">
     <label>
      30.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Morales
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <name>
        <surname>
         Gambhir
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
       <name>
        <surname>
         Bennett
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Stedman
        </surname>
        <given-names>
         HH
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Broader implications of progressive liver dysfunction and lethal sepsis in two boys following systemic high-dose AAV
      </article-title>
      <source>
       Mol. Ther.
      </source>
      <year>
       2020
      </year>
      <volume>
       28
      </volume>
      <fpage>
       1753
      </fpage>
      <lpage>
       1755
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsFKgsbbI
      </pub-id>
      <pub-id pub-id-type="pmid">
       32710826
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7363592
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ymthe.2020.07.009
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR31">
     <label>
      31.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Palazzi
        </surname>
        <given-names>
         X
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Biodistribution and tolerability of AAV-PHP.B-CBh-SMN1 in wistar han rats and cynomolgus macaques reveal different toxicologic profiles
      </article-title>
      <source>
       Hum Gene Ther.
      </source>
      <year>
       2022
      </year>
      <volume>
       33
      </volume>
      <fpage>
       175
      </fpage>
      <lpage>
       187
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xjs1yjtLc%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       34931542
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8885435
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1089/hum.2021.116
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR32">
     <label>
      32.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Schuster
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse
      </article-title>
      <source>
       Front. Neuroanat.
      </source>
      <year>
       2014
      </year>
      <volume>
       8
      </volume>
      <fpage>
       42
      </fpage>
      <pub-id pub-id-type="pmid">
       24959122
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4051274
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fnana.2014.00042
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR33">
     <label>
      33.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hinderer
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model
      </article-title>
      <source>
       Mol. Genet. Metab.
      </source>
      <year>
       2016
      </year>
      <volume>
       119
      </volume>
      <fpage>
       124
      </fpage>
      <lpage>
       130
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC28XhtFantL%2FM
      </pub-id>
      <pub-id pub-id-type="pmid">
       27386755
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5240037
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ymgme.2016.06.006
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR34">
     <label>
      34.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Mullard
        </surname>
        <given-names>
         A
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Gene therapy community grapples with toxicity issues, as pipeline matures
      </article-title>
      <source>
       Nat. Rev. Drug Discov.
      </source>
      <year>
       2021
      </year>
      <volume>
       20
      </volume>
      <fpage>
       804
      </fpage>
      <lpage>
       805
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXitlOlu7vM
      </pub-id>
      <pub-id pub-id-type="pmid">
       34599291
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/d41573-021-00164-x
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR35">
     <label>
      35.
     </label>
     <mixed-citation publication-type="other">
      Hordeaux, J. et al. MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates.
      <italic>
       Sci. Transl. Med.
      </italic>
      <ext-link ext-link-type="doi" xlink:href="10.1126/scitranslmed.aba9188">
       https://doi.org/10.1126/scitranslmed.aba9188
      </ext-link>
      (2020).
     </mixed-citation>
    </ref>
    <ref id="CR36">
     <label>
      36.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hamilton
        </surname>
        <given-names>
         BA
        </given-names>
       </name>
       <name>
        <surname>
         Wright
        </surname>
        <given-names>
         JF
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Challenges posed by immune responses to AAV vectors: addressing root causes
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2021
      </year>
      <volume>
       12
      </volume>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhs1Whu7vP
      </pub-id>
      <pub-id pub-id-type="pmid">
       34084173
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8168460
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2021.675897
      </pub-id>
      <elocation-id>
       675897
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR37">
     <label>
      37.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hordeaux
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Adeno-associated virus-induced dorsal root ganglion pathology
      </article-title>
      <source>
       Hum. Gene Ther.
      </source>
      <year>
       2020
      </year>
      <volume>
       31
      </volume>
      <fpage>
       808
      </fpage>
      <lpage>
       818
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhs1KltL%2FK
      </pub-id>
      <pub-id pub-id-type="pmid">
       32845779
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1089/hum.2020.167
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR38">
     <label>
      38.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Keiser
        </surname>
        <given-names>
         MS
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain
      </article-title>
      <source>
       Nat. Med.
      </source>
      <year>
       2021
      </year>
      <volume>
       27
      </volume>
      <fpage>
       1982
      </fpage>
      <lpage>
       1989
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXit1Ohs7%2FM
      </pub-id>
      <pub-id pub-id-type="pmid">
       34663988
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8605996
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41591-021-01522-3
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR39">
     <label>
      39.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kuzmin
        </surname>
        <given-names>
         DA
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       The clinical landscape for AAV gene therapies
      </article-title>
      <source>
       Nat. Rev. Drug Discov.
      </source>
      <year>
       2021
      </year>
      <volume>
       20
      </volume>
      <fpage>
       173
      </fpage>
      <lpage>
       174
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXlvFSgsbc%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33495615
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/d41573-021-00017-7
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR40">
     <label>
      40.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wei
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       In vivo CRISPR gene editing in patients with herpetic stromal keratitis
      </article-title>
      <source>
       Mol. Ther.
      </source>
      <year>
       2023
      </year>
      <volume>
       31
      </volume>
      <fpage>
       3163
      </fpage>
      <lpage>
       3175
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXhvV2hs7rO
      </pub-id>
      <pub-id pub-id-type="pmid">
       37658603
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ymthe.2023.08.021
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR41">
     <label>
      41.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Graham
        </surname>
        <given-names>
         FL
        </given-names>
       </name>
       <name>
        <surname>
         Smiley
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Russell
        </surname>
        <given-names>
         WC
        </given-names>
       </name>
       <name>
        <surname>
         Nairn
        </surname>
        <given-names>
         R
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Characteristics of a human cell line transformed by DNA from human adenovirus type 5
      </article-title>
      <source>
       J. Gen. Virol.
      </source>
      <year>
       1977
      </year>
      <volume>
       36
      </volume>
      <fpage>
       59
      </fpage>
      <lpage>
       74,
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DyaE2s3ivFGmtQ%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       886304
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1099/0022-1317-36-1-59
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR42">
     <label>
      42.
     </label>
     <mixed-citation publication-type="other">
      Choi, V. W., Asokan, A., Haberman, R. A. &amp; Samulski, R. J. Production of recombinant adeno-associated viral vectors for in vitro and in vivo use.
      <italic>
       Curr. Protoc. Mol. Biol.
      </italic>
      <ext-link ext-link-type="doi" xlink:href="10.1002/0471142727.mb1625s78">
       https://doi.org/10.1002/0471142727.mb1625s78
      </ext-link>
      (2007).
     </mixed-citation>
    </ref>
    <ref id="CR43">
     <label>
      43.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Zolotukhin
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield
      </article-title>
      <source>
       Gene Ther.
      </source>
      <year>
       1999
      </year>
      <volume>
       6
      </volume>
      <fpage>
       973
      </fpage>
      <lpage>
       985
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DyaK1MXjvVSit7o%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       10455399
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/sj.gt.3300938
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR44">
     <label>
      44.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Aurnhammer
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences
      </article-title>
      <source>
       Hum. Gene Ther. Methods
      </source>
      <year>
       2012
      </year>
      <volume>
       23
      </volume>
      <fpage>
       18
      </fpage>
      <lpage>
       28
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC3sXpvVyjurk%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       22428977
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1089/hgtb.2011.034
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR45">
     <label>
      45.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Jerome
        </surname>
        <given-names>
         KR
        </given-names>
       </name>
       <name>
        <surname>
         Huang
        </surname>
        <given-names>
         ML
        </given-names>
       </name>
       <name>
        <surname>
         Wald
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <name>
        <surname>
         Selke
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Corey
        </surname>
        <given-names>
         L
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR
      </article-title>
      <source>
       J. Clin. Microbiol.
      </source>
      <year>
       2002
      </year>
      <volume>
       40
      </volume>
      <fpage>
       2609
      </fpage>
      <lpage>
       2611
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD38XlvVSrtbY%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       12089286
      </pub-id>
      <pub-id pub-id-type="pmcid">
       120597
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1128/JCM.40.7.2609-2611.2002
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR46">
     <label>
      46.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Schindelin
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Fiji: an open-source platform for biological-image analysis
      </article-title>
      <source>
       Nat. Methods
      </source>
      <year>
       2012
      </year>
      <volume>
       9
      </volume>
      <fpage>
       676
      </fpage>
      <lpage>
       682
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC38XhtVKnurbJ
      </pub-id>
      <pub-id pub-id-type="pmid">
       22743772
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/nmeth.2019
      </pub-id>
     </mixed-citation>
    </ref>
   </ref-list>
  </ref-list>
  <app-group>
   <app id="App1" specific-use="web-only">
    <sec id="Sec27">
     <title>
      Viungo vya kusimamia
     </title>
     <p id="Par47">
      <supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_47940_MOESM1_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Supplementary Information
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM2" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_47940_MOESM2_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Peer Review File
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM3" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_47940_MOESM3_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Reporting Summary
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
    <sec id="Sec28">
     <title>
      Viungo vya kusimamia
     </title>
     <p id="Par48">
      <supplementary-material content-type="local-data" id="MOESM4" xlink:title="Source data">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2024_47940_MOESM4_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Source Data
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
   </app>
  </app-group>
  <notes notes-type="ESMHint">
   <title/>
   <p>
    The online version contains supplementary material available at
    <ext-link ext-link-type="doi" xlink:href="10.1038/s41467-024-47940-y">
     https://doi.org/10.1038/s41467-024-47940-y
    </ext-link>
    .
   </p>
  </notes>
  <notes notes-type="Misc">
   <p>
    <bold>
     Publisher’s note
    </bold>
    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
   </p>
  </notes>
 </back>
</article>
